Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIERCE: pembrolizumab + lenvatinib for advanced vulvar squamous cell carcinoma
2024-515646-16-00Phase 2Authorised
- Sponsor
- AGO Research
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in vulvar squamous cell carcinoma (VSCC), sponsored by AGO Research. Primary endpoint: Objective response rate within 24 weeks. Planned start Jun 2025; status: authorised.
02
Drugs
pembrolizumablenvatinib
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on 2024-515646-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515646-16-00.